AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02059200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Compassionate Living
Description: The MBCL program consists of eight biweekly group sessions of 2.5 hours, in which the participants get formal meditation exercises, some theoretical information and participate in inquiry on the meditation exercises and homework assignments. Homework assignments are given after every session, consisting of formal and informal meditation exercises primarily and some diary instructions.
Study NCT01212185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin spray
Description: 6 insufflations (24 IU of oxytocin total) given twice daily for 3 days
Study NCT01212185 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: intranasal spray without oxytocin
Description: 6 insufflations (0.1 metered dose/insufflation) twice daily
Study NCT02653222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal sympathicolysis
Study NCT02653222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulatory Blood Pressure Monitoring
Description: 1 month before and after surgery the patient will have an ABPM over 24h
Study NCT02653222 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Angiography
Description: 1 month before and after surgery the patient will have a MRA
Study NCT02653222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test
Description: complete blood count, blood platelets, coagulation profile, irregular agglutinins search
Study NCT02087904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-981
Study NCT00355394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Intravenous bolus administration.
Study NCT00355394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard care including intravenous fluid, but no metoclopramide.
Study NCT01999582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept is dosed intravenously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
Study NCT01999582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept is dosed subcutaneously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
Study NCT02237430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MynxGrip
Description: Closure device for femoral artery access closure
Study NCT02237430 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression
Description: Conventional manual compression
Study NCT01788007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod Topical Cream 3.75%
Description: Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
Study NCT01788007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyclara® (imiquimod) Topical Cream 3.75%
Description: Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
Study NCT01788007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Cream
Description: Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
Study NCT01207557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education Only
Description: 50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
Study NCT01207557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education Plus OIDA
Description: 50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
Study NCT04282772 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Impacted
Description: Until an active treatment for the PFM is started or the early exfoliation of PSM occurs, the tooth remains in a self-locking position
Study NCT04282772 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Self-corrected
Description: The ectopic erupted permanent molar can disregard the self-locking position and continue in a normal direction, but the distal root of the PSM remains more or less a significant atypical resorption
Study NCT03326141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program
Description: The program has been adapted for groups and includes 5 flexibility movements (e.g., back extension and ankle, head, neck, trunk movements), 5 leg strengthening exercises (knee extensor, knee flexor, hip abductor, ankle plantar flexes, ankle dorsiflexes), 12 balance movements (knee bends, backwards walking, walking and turning, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, heel-toe walking backwards, sit to stand, stair walking), and a walking plan. The number, intensity and duration of movements are individualized according to preference and ability and they are gradually progressed.
Study NCT03326141 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Otago Exercise Program
Description: The program has been adapted for groups and includes 5 flexibility movements (e.g., back extension and ankle, head, neck, trunk movements), 5 leg strengthening exercises (knee extensor, knee flexor, hip abductor, ankle plantar flexes, ankle dorsiflexes), 12 balance movements (knee bends, backwards walking, walking and turning, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, heel-toe walking backwards, sit to stand, stair walking), and a walking plan. The number, intensity and duration of movements are individualized according to preference and ability and they are gradually progressed.
Study NCT03326141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical activity monitors (e.g., Fitbit)
Description: We will use Fitbit Charge 2 (or an equivalent). Features essential for this research include built-in accelerometers that accurately measure steps and physical activity (PA) duration.Participants will have a brief orientation to these during baseline data collection and have the opportunity to return demonstrate. In addition, RAs will be available to help participants troubleshoot, as needed, via telephone and in person, after intervention meetings. Intervention meetings include discussions about the PAMs, but topics vary according to assigned study condition.
Study NCT03326141 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity monitors (e.g., Fitbit)
Description: We will use Fitbit Charge 2 (or an equivalent). Features essential for this research include built-in accelerometers that accurately measure steps and physical activity (PA) duration.Participants will have a brief orientation to these during baseline data collection and have the opportunity to return demonstrate. In addition, RAs will be available to help participants troubleshoot, as needed, via telephone and in person, after intervention meetings. Intervention meetings include discussions about the PAMs, but topics vary according to assigned study condition.
Study NCT03326141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Behavior Change Strategies
Description: The interpersonal content will include facilitated discussed about including PA into social routines, identifying and problem-solving social and environmental barriers to PA, social support for exercise, and friendly social comparisons about practicing PA outside the small group setting and interpreting/ sharing data.
Study NCT03326141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intrapersonal Behavior Change Strategies
Description: The intrapersonal content will include encouragement and guidance to identify baseline PA patterns, develop and refine personally meaningful goals and plans, identify and problem solve personal barriers to staying physically active, integrate PA into personal routines, and monitor goal outcomes
Study NCT03326141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information about Health and Wellness
Description: Information about health and wellness varies in dose, according to time spent in each condition that addresses behavior change. Topics in condition 1 include sleep, vaccinations, supplements, fall risk factors, memory, hearing and pain guided by information for older adults available on the NIA and CDC websites. Topics in conditions 2 and 3 include fall risk factors and sleep. Topics in condition 4 include fall risk factors.
Study NCT00632801 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: chewing gum
Description: The patients in the gum chewing group (intervention group) will chew one stick of gum the first post-operative day, after the nasogastric tube is removed or if they patient does not have a nasogastric tube, with the head of bed elevated a minimum of 30 degrees for 30 minutes, three times a day at set intervals
Study NCT00495651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral medications
Description: Antiretroviral medications initiation at any time during the trial if at least one WHO-recommended criterion for starting ART is observed.
Study NCT00495651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral medications+Isoniazid prophylaxis
Description: * Antiretroviral initiation at any time during the trial if at least one 2009 WHO-recommended criterion for starting ART is observed.~* Isoniazid prophylaxis:300 mg of INH once a day before breakfast for six months, starting one month after study inclusion
Study NCT00495651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral medications
Description: Early ART initiation on the day of inclusion, before reaching the current WHO criteria
Study NCT00495651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral medications+Isoniazid prophylaxis
Description: * Early Antiretroviral medications initiation on the day of inclusion, before reaching the current WHO criteria~* Isoniazid prophylaxis: 300 mg of INH once a day before breakfast for six months, starting one month after study inclusion
Study NCT03861637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESA for correction of PTA to 12-13g/dl
Description: To assess the impact of full correction of chronic PTA(to near normal values) on cardiovascular system and quality of life in renal transplant recipients with stable graft function using erythropoietin stimulating agents in comparison to partially treated PTA with HB level between 12-13g/dl.
Study NCT03067272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemBloc® Permanent Contraceptive System
Description: The FemBloc Permanent Contraceptive System consists of treatment with a Delivery System and Biopolymer, and a confirmation test with the FemChec® Tubal Occlusion Confirmation device as part of a sonographic hysterosalpingogram (Sono HSG).
Study NCT02690129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Progesteron
Study NCT02690129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal Progesteron
Study NCT00774345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules given orally on days 1-28 of a 28 day cycle
Study NCT00774345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules given orally on days 1 - 28 of a 28 day cycle
Study NCT01899170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Implantation of a deep brain stimulation electrode into pain processing brain areas
Study NCT01899170 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation
Description: Implantation of a deep brain stimulation electrode into pain processing brain areas
Study NCT01899170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervel Neurotech, Multi-coil TMS
Description: Non-invasive selective stimulation of deep brain areas using magnetic fields.
Study NCT01899170 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cervel Neurotech, Multi-coil TMS
Description: Non-invasive selective stimulation of deep brain areas using magnetic fields.
Study NCT01899170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervel Neurotech, Multi-coil TMS
Description: Non-invasive selective stimulation of deep brain areas using magnetic fields.
Study NCT01899170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-Carfentanil
Description: PET-radioligand for functional brain imaging to assess opioid binding. The compound is a potent synthetic opioid.
Study NCT01899170 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 11C-Carfentanil
Description: PET-radioligand for functional brain imaging to assess opioid binding. The compound is a potent synthetic opioid.
Study NCT01899170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Carfentanil
Description: PET-radioligand for functional brain imaging to assess opioid binding. The compound is a potent synthetic opioid.
Study NCT02680379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline, then Minocycline/Lovastatin
Description: Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.
Study NCT02680379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin, then Minocycline/Lovastatin
Description: Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.
Study NCT02462473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
Study NCT02462473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
Study NCT02462473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.
Study NCT02462473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
Study NCT02462473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.
Study NCT04395911 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SCD
Description: cytopheretic device
Study NCT01103674 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Numeris®-AF Guided Coagulation System with VisiTrax®
Description: Combined epicardial / endocardial procedure using the Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the Biosense Webster ThermoCool Catheter in conjunction with the Carto Navigation System endocardially.
Study NCT02014064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: MA Group: Dispense 1 cap @ 8 AM on Treatment day 9 and 10 (total daily dose 40mg or 0); 1 cap SID @ 8 AM and 4 PM on day 11,12, and 13 (total daily dose 80mg or 0); 1 cap @ 8 AM on day 14 (total daily dose, 40mg or 0).~Control Group Schedule:~* Day 1: 40mg @ 8:00am~* Day 2: 40mg @ 8:00am~* Day 3: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 4: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 5: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 6: 40mg @ 8:00am = Testing day (fMRI scan \& cognitive testing session)
Study NCT02014064 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control Group: Day 1: 40mg @ 8am Day 2: 40mg @ 8am Day 3: 40mg @ 8am, 40mg @ 8pm Day 4: 40 mg @ 8am, 40mg @ 8pm Day 5: 40mg @ 8am, 40 mg @ 8pm Day 6: 40 mg @ 8am = Testing day (fMRI scan \& cognitive testing session)
Study NCT04779203 — intervention group
Intervention type: DEVICE
Intervention: Osseodensification Densah Bur
Description: Implants placed with osseodensification surgical drilling compared to those placed with subtractive conventional drilling technique in a split-mouth design will result: 1) in the same insertion torque values and; 2) in the same implant stability quotient values when measured immediately after implant placement and after 1, 2, 3, 4, 5, 6, 7, 8, and 12 weeks.
Study NCT01637233 — intervention group
Intervention type: DRUG
Intervention: Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors
Description: NRTI+PI
Study NCT01637233 — intervention group
Intervention type: DRUG
Intervention: Arm 2 Maraviroc and Protease Inhibitors
Description: maraviroc + PI
Study NCT01637233 — intervention group
Intervention type: DRUG
Intervention: Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors
Description: maraviroc + NRTI
Study NCT00278681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc and ORS
Description: One strip containing 14 dispersible zinc tablets (20 mg each) along with 2 ORS packets were prescribed to all children aged 1 month to 5 years visiting that channel with diarrhea.~Infants aged less than 6 months were advised half a zinc tablet in a teaspoonful of breast milk; older children were advised 1 tablet in breast milk or clean water.
Study NCT03138876 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EEG Cap
Description: Patient will be fitted with an EEG cap by the on-call neurology resident to assess for NCSE.
Study NCT03138876 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anti-seizure medication
Description: Patients may be treated for NCSE or seizures based on EEG cap findings, if the findings are clear to an attending EEG reviewer. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
Study NCT03138876 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard EEG
Description: An electroencephalogram (EEG) is a test used to find problems related to electrical activity of the brain. An EEG tracks and records brain wave patterns. Small metal discs with thin wires (electrodes) are placed on the scalp, and then send signals to a computer to record the results.
Study NCT03842020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pharmacokinetic samples
Description: 1 or 3 sample(s) will be taken in the following time windows: \[H0-H3\]; \[H5-H9\] and just before the next set \[H24\], depending if the child is or is not admitted to hospital
Study NCT01791608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc sulfate as dietary supplementation
Description: Zinc sulfate as dietary supplementation
Study NCT01791608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc amino acid chelate as dietary supplementation
Description: Zinc amino acid chelate as dietary supplementation
Study NCT01791608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk without fortification without zinc
Description: Milk without fortification
Study NCT02204696 — intervention group
Intervention type: PROCEDURE
Intervention: Tonsillectomy
Description: Study participants will be scheduled for tonsillectomy based on clinical indications, with the need for surgery determined prior to study enrollment and not based on study enrollment.
Study NCT01418976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Mobility Training (IMT)
Description: Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
Study NCT04429061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SKILLZ-Girl curriculum
Description: Participation in the SKILLZ-Girl curriculum and SKILLZ-Club
Study NCT01158521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity.
Study NCT01158521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
Study NCT03934983 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study NCT00781716 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug eluting coronary stent system
Description: Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System
Study NCT02087904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo